Director, Global Regulatory Affairs leading Protara's ex - US regulatory strategy and operational execution for clinical studies in oncology, cell and gene therapy, and rare diseases.

Protara is committed to advancing transformative therapies for people with cancer and rare diseases.
Protara’s portfolio includes its lead program, TARA-002, an investigational cell therapy in development for the treatment of non-muscle invasive bladder cancer and lymphatic malformations, and IV Choline Chloride, an investigational, intravenous phospholipid substrate replacement therapy in development for the treatment of intestinal failure-associated liver disease.
For more information, visit www.protaratx.com.
Browse and apply for open jobs at Protara Therapeutics.
Director, Global Regulatory Affairs leading Protara's ex - US regulatory strategy and operational execution for clinical studies in oncology, cell and gene therapy, and rare diseases.